Login to Your Account

IVAX's Former CEO Invests $15M

Shell Firm Acquiring Protalix, Phase III Gaucher's Therapy

By Randall Osborne

Wednesday, August 23, 2006
Public shell company Orthodontix Inc. is gaining a Phase III-ready drug for Gaucher's disease along with a plant-cell bioreactor for making proteins in its merger with Israeli firm Protalix Ltd. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription